Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

    ... hemoglobinuria (PNH) or myelodysplastic syndrome (MDS) associated with cytopenias. Patients with BMFS have traditionally been ... primary endpoint of this study will be cGVHD at day 365. Secondary end points include transplant related mortality, engraftment, degree ...

    Clinical Trial last updated 04/28/2016 - 2:40pm.

  2. Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

    ... (KPT-330) that we can give to patients with leukemia or MDS, when it is combined with fludarabine and cytarabine. The goal of the ... leukemia (MPAL) and myelodysplastic syndrome (MDS). SECONDARY OBJECTIVES: To characterize the pharmacokinetics of selinexor, ...

    Clinical Trial last updated 04/28/2016 - 9:48am.

  3. CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

    ... . To determine how often primary graft failure and secondary graft failure occurs in the children, adolescents and young adults ... aplastic anemia myelodysplastic syndromes (MDS) Associated Drug(s):  ...

    Clinical Trial last updated 04/28/2016 - 8:36am.

  4. A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

    ... . Subjects with intermediate-1, intermediate-2 or high risk MDS by IPSS, and baseline platelet count of <75 Giga (10^9) per liter (Gi/L) ... free during the first 4 cycles of azacitidine therapy. Key secondary endpoints include overall survival, disease response, and disease ...

    Clinical Trial last updated 04/27/2016 - 1:28pm.

  5. Safety Study of Cord Blood Units for Stem Cell Transplants

    ... administration of unlicensed, investigational NCBP CBU. Secondary Objectives: In patients receiving a non-licensed NCBP CBU ... aplastic anemia myelodysplastic syndromes (MDS) Phase:  ...

    Clinical Trial last updated 04/27/2016 - 2:25pm.

  6. Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome

    ... aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are life-threatening bone marrow disorders. For SAA patients, long ... related donor might promote rapid engraftment and reduce TRM secondary to prolonged neutropenia associated with conventional UCBT. This ...

    Clinical Trial last updated 04/25/2016 - 2:18pm.

  7. Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

    ... hemoglobinuria (PNH) or myelodysplastic syndrome (MDS) associated with cytopenias. Patients with BMFS have traditionally been ... primary endpoint of this study will be cGVHD at day 365. Secondary end points include transplant related mortality, engraftment, degree ...

    Clinical Trial last updated 04/25/2016 - 10:08am.

  8. Bone Marrow Transplant

    ... doctor about bone marrow transplant options. MDS : Whether patients with MDS should undergo hematopoietic stem cell transplantation (HSCT) as soon as ... can also affect SCT outcomes. People with secondary MDS , caused by a previous treatment for another disease or ...

    Topic section last updated 03/29/2016 - 7:27pm.

  9. Joan Latsko, DNP, CRNP, OCN, AOCNP

    ... Joan lectures on myelodysplastic syndromes (MDS) and other relevant hematology disorders at local, state, and ... professional medical conferences. She has been a primary and secondary author in several publications on MDS generated by The Western Pennsylvania Hospital and Cancer Institute. ...

    Bio last updated 03/11/2016 - 1:41pm.

  10. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... The myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal myeloid malignancies ... (AML). AML, which can occur de novo as well as secondary to MDS, is characterized by malignant clones of myeloid lineage in ...

    Research Article last updated 12/09/2015 - 8:49am.